- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07353736
Cerebral Arteriovenös Malformation med Aneurysm: Epidemiologi, Kliniska Drag och Prognos
Hemodynamiska mekanismer, kliniska profiler och prognostiska faktorer hos patienter med cerebrala arteriovenösa malformationer och intrakraniella aneurysmer: En observationsstudie
The study is a multicenter, prospective cohort study designed to assess the natural history, clinical safety and efficacy of various treatment strategies in patients with cerebral arteriovenous malformations (AVMs) and intracranial aneurysms.
Studieöversikt
Status
Detaljerad beskrivning
This study aims to evaluate the clinical safety and efficacy of different treatment strategies in patients with cerebral arteriovenous malformations (AVMs) combined with intracranial aneurysms (IAs) through a multicenter, large-sample, prospective observational cohort study. It will comprehensively analyze the epidemiological characteristics, clinical manifestations, associated risk factors, natural disease progression, and bleeding risks, as well as explore the hemodynamic mechanisms and genetic background differences. Clinical data, imaging findings, and blood samples will be collected from patients to investigate the impact of hemodynamics on aneurysm formation, rupture risk, and treatment outcomes. Additionally, the study will explore the genetic differences of AVM and IA patients and their correlation with clinical presentation and prognosis, ultimately providing a scientific basis for individualized treatment strategies.
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Xin Feng, MD
- Telefonnummer: +86 13681134001
- E-post: 13681134001@163.com
Studieorter
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 528400
- Rekrytering
- Zhujiang Hospital, Southern Medical University
-
Kontakt:
- Xin Feng, MD
- Telefonnummer: +86 13681134001
- E-post: 13681134001@163.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients treated across eight neurosurgery centers who were confirmed by digital subtraction angiography (DSA), and/or magnetic resonance imaging (MRI), computed tomographic angiography (CTA) to have cerebral arteriovenous malformation and intracranial aneurysm.
Beskrivning
Inclusion Criteria:
- Patients diagnosed with cerebral arteriovenous malformation and intracranial aneurysm confirmed by CTA, MRA, and/or DSA;
- Availability of complete clinical and imaging data;
- Provision of written informed consent by the patient or their legally authorized representative to participate in the study and undergo follow-up;
- Not concurrently participating in any other clinical trials that may interfere with the outcomes of this study.
Exclusion Criteria:
- Previous complete occlusion of the aneurysm and/or arteriovenous malformation prior to enrollment;
- Coexistence of other cerebrovascular diseases such as moyamoya disease, cerebral cavernous malformation, cerebral venous sinus thrombosis, etc.;
- Absence of DSA imaging data or poor image quality that precludes accurate evaluation of key anatomical and hemodynamic parameters of the AVM and intracranial aneurysm.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Patients diagnosed with cerebral arteriovenous malformations and intracranial aneurysms
Patients diagnosed with concomitant cerebral arteriovenous malformations and intracranial aneurysms by digital subtraction angiography (DSA), and/or magnetic resonance imaging (MRI), and/or computed tomographic angiography (CTA). |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Imaging Treatment Success Rate of Target Vascular Lesions
Tidsram: 3 months postoperatively, 6 months postoperatively, 1years postoperatively, and 2 years postoperatively
|
his is a composite endpoint with stratified reporting by lesion type. It will separately calculate and report the success rates for the following two patient cohorts: For patients with intracranial aneurysms: Treatment success is defined as complete occlusion on postoperative digital subtraction angiography, assessed as Class I by the Raymond-Roy Occlusion Classification (RROC) or as Grade D by the O'Kelly-Marotta (OKM) grading scale. For patients with cerebral arteriovenous malformations (AVMs): Treatment success is defined as complete embolization on postoperative digital subtraction angiography, confirmed by the core laboratory or two independent assessors with no residual nidus opacification. Critical clarification: This composite measure does NOT calculate an overall arithmetic combined success rate. The final reported values will be two independent percentages. |
3 months postoperatively, 6 months postoperatively, 1years postoperatively, and 2 years postoperatively
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of perioperative complications
Tidsram: Perioperative period
|
Perioperative complications include technical related complications (vascular rupture, thrombosis, etc.) and clinical complications (neurological deficits, infections, etc.) |
Perioperative period
|
|
Proportion of patients with hemorrhagic complications during follow-up period
Tidsram: within three years
|
Including the type of bleeding (intracerebral hemorrhage/subarachnoid hemorrhage/intraventricular hemorrhage), specific location of bleeding,amount of bleeding;and determination of bleeding source: determine the source of bleeding from malformation or aneurysm through imaging examination. |
within three years
|
|
Proportion of patients with poor functional prognosis
Tidsram: 3 months postoperatively, 6 months postoperatively,and one year postoperatively
|
mRS score 3-6 |
3 months postoperatively, 6 months postoperatively,and one year postoperatively
|
|
Proportion of patients with good functional prognosis
Tidsram: 3 months postoperatively, 6 months postoperatively,and one year postoperatively
|
mRS score 0-2 |
3 months postoperatively, 6 months postoperatively,and one year postoperatively
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Chuanzhi Duan, MD, Zhujiang Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Cerebrovaskulära störningar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Patologiska processer
- Blödning
- Medfödda abnormiteter
- Kardiovaskulära avvikelser
- Missbildningar i nervsystemet
- Aneurysm
- Intrakraniella blödningar
- Vaskulära missbildningar
- Arteriovenösa missbildningar
- Centrala nervsystemet Vaskulära missbildningar
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Patologiska tillstånd, tecken och symtom
- Hjärnsjukdomar
- Hjärnblödning
- Intrakraniell aneurysm
- Intrakraniella arteriovenösa missbildningar
- Intrakraniella arteriella sjukdomar
Andra studie-ID-nummer
- LC2016ZD032
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .